Skip to content
Toggle main navigation
PURPOSE logo
PURPOSE logo
  • Home
  • Events
  • Opportunities
  • News & Publications
  • T90/R90 HEAL Pain Cohort Program
  • Mobile App
  • About
  • Exhibit
  • Affiliate Networks
    • Music4Pain (U24)
    • ENSEMBLE Network (U24)
    • Pain Research Forum (PRF)
    • ForceNET (U24)
    • NeuronS_MATTR (U24)
    • SPINEWORK Network (U24)
    Log in
    Request to Join

    News & Publications

    Do you have news or publications to share with the PURPOSE Network? Submit your news below.

    Submit Your News or Publication
    All
    Acquired Cognitive Impairment
    Acupuncture
    Addiction
    Ageing
    Alcohol Use / Alcohol Use Disorder (AUD)
    Analgesics
    Analgesics, Topical
    Anatomy
    Anesthesia, General
    Anesthesia, Intravenous regional
    Anesthesia, Local
    Anesthesia, Spinal
    Animal Models
    Anxiety
    Arthritis, Rheumatoid
    See all

    Highlighted News

    Results (18)

    Mechanical Compression-Induced Peripheral Neuropathic Pain: From Astrocyte Mechanosensing and Phenotypic Reprogramming to CCL2-CCR2 Axis-Targeted Therapies

    Mechanical Compression-Induced Peripheral Neuropathic Pain: From Astrocyte Mechanosensing and Phenotypic Reprogramming to CCL2-CCR2 Axis-Targeted Therapies

    J Inflamm Res. 2026 Oct 14;19:634895. doi: 10.2147/JIR.S634895. eCollection 2026.ABSTRACTNeuropathic pain (NP) arising from mechanical nerve compression is driven by central sensitization, in which reactive astrocytes and chemokine-mediated neuro-glial crosstalk act as master regulators. Among candidate chemokine axes, the C-C motif chemokine ligand 2 (CCL2) and its receptor, C-C chemokine recepto
    October 20, 2026
    AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

    AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

    Mater Today Bio. 2026 Oct 5;41:103726. doi: 10.1016/j.mtbio.2026.103726. eCollection 2026 Dec.ABSTRACTNeuropathic pain (NP) remains a major clinical challenge as current medications are ineffective in treating the underlying cause, and the clinical use of these drugs also has adverse reactions such as addiction. Therefore, specialized pro-resolving mediators (SPMs) may represent a promising therap
    October 20, 2026
    Now Available: Developing Peptide Therapeutics For Targeted Pain Management

    Now Available: Developing Peptide Therapeutics For Targeted Pain Management

    New Video Available: Developing Peptide Therapeutics For Targeted Pain ManagementWatch the full presentation now in the Media CenterIn Episode 18 of the PURPOSE Professional Series, Eric Gross, MD, PhD, presents peptide therapeutics as non-opioid strategies to control acute postsurgical pain and prevent chronic pain development. Dr. Gross highlights an intracellular TRPV1 peptide decoy derived fro
    September 19, 2026
    K2P channels as emerging therapeutic targets for pain: insights from functional studies and transcriptomic analyses

    K2P channels as emerging therapeutic targets for pain: insights from functional studies and transcriptomic analyses

    Front Pharmacol. 2026 Sep 3;17:1907761. doi: 10.3389/fphar.2026.1907761. eCollection 2026.ABSTRACTTwo-pore domain potassium (K2P) channels are major determinants of neuronal excitability through their ability to generate leak potassium currents that control resting membrane potential and action potential firing. Initially considered as passive background channels, K2P channels are now recognized a
    September 18, 2026
    Cyclodextrins in chronic pain: Membrane cholesterol remodeling and neuroimmune signaling

    Cyclodextrins in chronic pain: Membrane cholesterol remodeling and neuroimmune signaling

    Biomed Pharmacother. 2026 Aug 27;203:119889. doi: 10.1016/j.biopha.2026.119889. Online ahead of print.ABSTRACTBACKGROUND: Chronic pain remains challenging to treat, with current therapies offering incomplete relief and significant side effects. This narrative review examines cyclodextrins (CDs) beyond their conventional excipient role, focusing on their emerging function as membrane-active modulat
    August 28, 2026
    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    New Video Available: Pain Mechanisms and TreatmentWatch the full presentation now in the Media CenterIn Episode 7 of the Exploring Pain series, host Laura Wandner, PhD, sits down with Ted Price, PhD, Director of the Center for Advanced Pain Studies at UT Dallas, to explore how molecular neuroscience is advancing precision pain medicine. Price highlights single-cell transcriptomic and proteomic fin
    August 25, 2026
    Engineering Nanoscale Drug Delivery Systems for Pain

    Engineering Nanoscale Drug Delivery Systems for Pain

    Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2026 Jul-Aug;18(4):e70072. doi: 10.1002/wnan.70072.ABSTRACTPain is a pervasive and multifaceted condition that imposes a significant medical and economic burden worldwide. This burden is underscored by the urgent need for transformative, non-addictive opioid alternatives. Nanomedicine offers a promising avenue for addressing the many limitations associ
    August 7, 2026
    Kappa opioid receptors in excitatory spinal neurons gate acute pain: evidence from mouse and human

    Kappa opioid receptors in excitatory spinal neurons gate acute pain: evidence from mouse and human

    bioRxiv [Preprint]. 2026 Jul 6:2026.07.01.735618. doi: 10.64898/2026.07.01.735618.ABSTRACTThe kappa opioid receptor (KOR) has emerged as a promising, nonaddictive analgesic target, yet the neural mechanisms underlying KOR inhibition of pain are not entirely understood. Here, we provide converging evidence that KOR expressed on spinal neurons inhibits acute pain. We demonstrate that pharmacological
    July 17, 2026
    The Role of the Mitochondrial Permeability Transition Pore in Chronic Pain

    The Role of the Mitochondrial Permeability Transition Pore in Chronic Pain

    Curr Neuropharmacol. 2026 Jul 10. doi: 10.2174/011570159X487795260629095134. Online ahead of print.ABSTRACTThe mitochondrial Permeability Transition Pore (mPTP) has been implicated in cell death, energy failure, and oxidative stress. Emerging evidence suggests that mPTP may also contribute to the development and maintenance of chronic pain, although evidence remains limited and the underlying mech
    July 16, 2026
    Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms

    Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms

    Mol Biol Rep. 2026 Jun 18;53(1):937. doi: 10.1007/s11033-026-12098-x.ABSTRACTBACKGROUND AND PURPOSE: Neuropathic pain is a chronic and disabling condition characterized by persistent sensory hypersensitivity and inadequate treatment options. Neuroinflammation and TRPV1/CGRP-driven nociceptive pathways are critical contributors to its pathogenesis. Bergenin, a naturally occurring C-glucoside with e
    June 20, 2026
    Adenosine A2A receptor signaling in neuroinflammation, glial modulation, and mechanisms associated with chronic pain

    Adenosine A2A receptor signaling in neuroinflammation, glial modulation, and mechanisms associated with chronic pain

    Purinergic Signal. 2026 Jun 10;22(3):56. doi: 10.1007/s11302-026-10167-1.ABSTRACTChronic pain is increasingly recognized as a complex and multidimensional condition that extends beyond peripheral nociceptive input, encompassing maladaptive central mechanisms such as persistent neuroinflammation, glial dysfunction, aberrant synaptic plasticity, and disturbances in affective-motivational circuits. A
    June 10, 2026
    Decoding visceral pain: Molecular pathways and translational targets in gaseous signalling and pharmacology

    Decoding visceral pain: Molecular pathways and translational targets in gaseous signalling and pharmacology

    Br J Pharmacol. 2026 Jun 7. doi: 10.1111/bph.70526. Online ahead of print.ABSTRACTVisceral pain, a hallmark of many gastrointestinal (GI) disorders, remains a persistent clinical challenge due to its multifactorial pathophysiology and limited treatment options. Recent advances highlight the role of endogenous gaseous signalling molecules, hydrogen sulphide (H2S), nitric oxide (NO) and carbon monox
    June 9, 2026
    Recent advances in nanomaterial-based strategies for chronic pain alleviation

    Recent advances in nanomaterial-based strategies for chronic pain alleviation

    Mater Today Bio. 2026 May 23;38:103279. doi: 10.1016/j.mtbio.2026.103279. eCollection 2026 Jun.ABSTRACTChronic pain profoundly impacts global quality of life, positioning effective pain management as a critical medical priority. Currently, clinical pain treatment relies heavily on non-steroidal anti-inflammatory drugs and opioids, which, however, can lead to adverse effects and tolerance. Recent a
    June 4, 2026
    A novel TCF12-MAVS signaling axis in astrocytes promotes vincristine-induced neuropathic pain in male mice

    A novel TCF12-MAVS signaling axis in astrocytes promotes vincristine-induced neuropathic pain in male mice

    Brain Behav Immun. 2026 May 20:106829. doi: 10.1016/j.bbi.2026.106829. Online ahead of print.ABSTRACTChemotherapy-induced neuropathic pain (CINP) can be triggered by microtubule-targeting agents, including plant-derived vinca alkaloids such as vincristine (VCR). In a male mouse model of VCR-induced neuropathic pain (VINP), mitochondrial antiviral signaling protein (MAVS) expression was upregulated
    May 22, 2026
    CTRP3 alleviates neuropathic pain by improving mitochondrial biogenesis and mitochondrial unfolded protein response via spinal SIRT1 in rats

    CTRP3 alleviates neuropathic pain by improving mitochondrial biogenesis and mitochondrial unfolded protein response via spinal SIRT1 in rats

    Int J Mol Med. 2026 Jul;58(1):197. doi: 10.3892/ijmm.2026.5868. Epub 2026 May 22.ABSTRACTNeuropathic pain arises from an intricate network of interconnected pathophysiological mechanisms, yet the arsenal of effective therapeutic strategies remains frustratingly limited. Accumulating evidence has linked mitochondrial dysfunction to the progression of neuropathic pain. C1q‑tumor necrosis factor‑rela
    May 22, 2026
    Targeting Supramolecular Active Complexes of Na(v)1.7/Na(v)1.8 to Relieve Chronic Neuropathic Pain

    Targeting Supramolecular Active Complexes of Na(v)1.7/Na(v)1.8 to Relieve Chronic Neuropathic Pain

    Adv Sci (Weinh). 2026 May 20:e22185. doi: 10.1002/advs.202522185. Online ahead of print.ABSTRACTNeuropathic pain (NP) affects 7%-10% of population, with current treatments often proving inadequate. Here we show that Nav1.7 and Nav1.8 form supramolecular active complexes (SMACs) with polygonal lattice structure in dorsal root ganglion (DRG) neurons of mouse models and patients with severe chronic N
    May 20, 2026
    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    ACS Med Chem Lett. 2026 Apr 24;17(5):1189-1194. doi: 10.1021/acsmedchemlett.6c00132. eCollection 2026 May 14.ABSTRACTNaV1.8 is a key mediator of peripheral nociceptive signaling and an attractive nonopioid target for pain therapeutics. We report the discovery of MK 5661, a potent, selective, and orally bioavailable NaV1.8 inhibitor amenable to once-daily dosing. Optimization of an initial lead, gu
    May 20, 2026
    New HEAL Research Priorities Article | Engineering the Next Generation of Pain Therapeutics: A Shift Toward Mechanism-Based Discovery

    New HEAL Research Priorities Article | Engineering the Next Generation of Pain Therapeutics: A Shift Toward Mechanism-Based Discovery

    Accelerating the drug development pipeline requires bridging the gap between basic academic science and successful clinical translation. The latest installment in the HEAL Research Priorities series examines Priorities B and C, focusing on the rigorous development of novel, highly efficacious pharmaceutical modalities and the human-centric models needed to discover them.In this new interview, Step
    May 15, 2026
    Contact
    Neurovations Education
    [email protected]

    United States

    PURPOSE@PainResearchers.com
    707-260-0848
    Links
    • NIH HEAL Initiative
    • Research in Pain Management